Efficacy and safety of low molecular weight heparin, unfractionated heparin and warfarin for thrombo-embolism prophylaxis in orthopaedic surgery: A meta-analysis of randomised clinical trials

Pathophysiology of Haemostasis and Thrombosis

Volumn 27, Issue 2, 1997, Pages 75-84

  Palmer, A J ^a   Koppenhagen, K ^b   Kirchhof, B ^c   Weber, U ^d   Bergemann, R ^a  

^a Inst for Med Info and Biostatist   (Switzerland)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c Knoll AG   (Germany)

^d Orthopaedic Hospital   (Germany)

Author keywords

Low molecular weight heparin; Meta analysis; Orthopaedic surgery

Indexed keywords

ARDEPARIN; CERTOPARIN; DALTEPARIN; DANAPAROID; DIHYDROERGOTAMINE MESILATE; EMBOLEX; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PARNAPARIN; REVIPARIN; TINZAPARIN; UNCLASSIFIED DRUG; WARFARIN;

ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DEEP VEIN THROMBOSIS; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; ORTHOPEDIC SURGERY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOEMBOLISM;

ANTICOAGULANTS; HEMORRHAGE; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; ORTHOPEDICS; POSTOPERATIVE COMPLICATIONS; RANDOMIZED CONTROLLED TRIALS; THROMBOEMBOLISM; WARFARIN;

EID: 0031001452     PISSN: 14248832     EISSN: 14248840     Source Type: Journal    
DOI: 10.1159/000217437     Document Type: Article

References (37)

1. Carter CJ, Kelton JG, Hirsh J, Cerskus A, Santos AV, Gent M: The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits. Blood 1982;59:1239-1245.
2. Nurmohamed MT, Rosendaal FR, Buller HR, Dekker E. Hommes DW, Vandenbroucke JP. Briet E: Low-molecular-weight heparin vs. Standard heparin in general and orthopaedic surgery: A meta-analysis. Lancet 1992,340:152-156.
3. Leizorovicz A, Haugh MC, Chapuis FR. Samama MM, Boissel JP: Low molecular weight heparin in prevention of perioperative thrombosis. Br Med J 1992;305:913-920.
4. Biiller HR, Lcnsing AWA. Hirsh J, Ten Cate JW: Deep venous thrombosis: New non-invasive diagnostic tests. Thromb Haemostas 1991;66: 133-137.
5. Cruickshank MK, Levine MN, Hirsh J, Turpie AG, Powers P, Jay R, Gent M: An evaluation of impedance plethysmography and ^Si-fibrinogen leg scanning in patients following hip surgery. Thromb Hac-most 1989;62:830-834.
6. Eddy DM, Hasselblad V: FAST*PRO-Software for Meta-Analysis by the Confidence Profile Method. San Diego, Harcourt Brace Jovanovich, 1992.
7. Leyvraz PF. Bachmann F, Hoek J, Buller HR. Postel M, Samama M, Vandenbroek MD: Prevention of deep vein thrombosis after hip replacement: Randomised comparison between unfractionatcd heparin and low molecular weight heparin. BMJ 1991;303:543-548.
8. Oertli D, Hess P, Durig M, Laffer U, Fridrich R, Jaeger K. Kaufmann R, Harder F: Prevention of deep vein thrombosis in patients with hip fractures: Low molecular weight heparin vs. dextran. World J Surg 1992; 16: 980-984: discussion 984-985.
9. Chiapuzzo E, Orengo GB, Ottria G, Chiapuzzo A, Palazzini E, Fusillo M: The use of low molecular weight heparins for postsurgical deep vein thrombosis prevention in orthopaedic patients. J Int Med Res 1988; 16:359-366.
10. Dechavanne M, Ville D, Berruyer M, Trepo F, Dalcry F, Clermont N, Lerat JL, Moyen B. Fischer LP, Kher A, Barbier P: Randomized trial of a low-molecular-weight heparin (Kabi 2165) vs. adjusted-dose subcutaneous standard heparin in the prophylaxis of deep-vein thrombosis after elective hip surgery. Haemostasis 1989;19:5-12.
11. Eriksson BI, Zachrisson BE, Teger-Nilsson AC, Risberg B: Thrombosis prophylaxis with low molecular weight heparin in total hip replacement. Br J Surg 1988;75:1053-1057.
12. Lassen M R, Borris LC, Christ iansen HM, Moller-Larsen F, Knudsen VE, Boris P, Nehen AM, de Carvalho A, Jurik AG, Nielsen BW, Lucht U: Heparin/dihydroergotamine for venous thrombosis prophylaxis: Comparison of low-dose heparin and low-molecular w eight heparin in hip surgery. Br J Surg 1988;75:686-689.
13. Monreal M, Lafoz E, Navarro A, Granero X, Caja V, Caccres E, Salvador R, Ruiz J: A prospective double-blind trial of a low molecular weight heparin once daily compared with conventional low-dose heparin three times daily to prevent pulmonary embolism and venous thrombosis in patients with hip fracture. J Trauma 1989:29:873-875.
14. Pini M, Tagliaferri A, Manotti C, Lasagni F, Rinaldi E, Dettori AG: Low molecular weight heparin (alfa lmwh) compared with unfractionated heparin in prevention of deep-vein thrombosis after hip fractures. Int Angiol 1989;8:134-139.
15. Planes A, Vochelle N, Mazas F, Mansat C, Zucman J, Landais A, Pascariello JC, Weill D, Butcl J: Prevention of postoperative venous thrombosis: A randomized trial comparing unfractionated heparin with low molecular weight heparin in patients undergoing total hip replacement. Thromb Haemost 1988; 60:407-410.
16. Levine MN, Hirsh J: An overview of clinical trials of low molecular weight heparin fractions. Acta Chir Scand Suppl 1988;543:73-79.
17. Barre J, Pfister G, Potron G, Droulle C, Baudrillard JC, Barbier P, Kher A: Efficacité et tolérance comparée du Kabi 2165 et de l’héparine standard dans la prévention des thromboses veineuses profondes au cours des prothèses totales de hanche. J Mal Vase 1987; 12(suppl B): 90-95.
18. Turpie AG, Levine MN. Hirsh J, Carter CJ, Jay RM. Powers PJ, Andrew M, Hull RD, Gent M: A randomized controlled trial of a low-molecular-weight heparin (Enoxa-parin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. N Engl J Med 1986;315: 925-929.
19. Besson L, Azzar D, Davidas JL, Massignon D, Rändelet B, Bansillon V, Dejour H: Efficacy and safety of CY 216 in the prevention of deep vein thrombosis after total hip replacement. New York. Schattauer, 1919. p 127.
20. Boris LC, Hauch O. Jorgensen LN, Lassen MR: Low-molecular-weight heparin (Enoxaparin) vs. dextran 70. The Danish Enoxaparin Study Group. Arch Intern Med 1991; 151: 1621-1624.
21. Estoppey D, Hochreiter J, Breyer HG, Jakubek H, Leyvraz PF, Haas S, Stickema JCJ: ORG 10172 (Lo-moparan) vs. heparin-DHE in prevention of thromboembolism in total hip replacement-a multicentre trial. Thromb Haemost 1989:62: 356.
22. Planes A: Comparison of antithrombotic efficacy and haemorrhagic side-effects of Clivarin vs. Enoxaparin in patients undergoing total hip replacement surgery. Blood Coa-gul Fibrinolysis 1993;4(suppl 1): S33-S35; discussion S37-S38.
23. The RD Heparin Arthroplasty Group: RD heparin compared with warfarin for prevention of venous thromboembolic disease following total hip or knee arthroplasty. J Bone Joint Surg 1994;76:1174-1185.
24. Hull R, Raskob G, Pineo G, Rosen-bloom D, Evans W, Mallory T, An-quist K, Smith F, Hughes G, Green D, Elliott G, Panju A, Brant R: A comparison of subcutaneous low-molccular-wcight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med 1993;329:1370-1376.
25. Mätzsch T, Bergqvist D, Fredin H, Hedner U. Lindhagcn A, Nistor L: Comparison of the thromboprophy-lactic effect of a low molecular weight heparin vs, dextran in total hip replacement. Thromb Hac-morrh Disord 1991;3:25-29.
26. Haas S, Stemberger A, Fritschc IIM, Welzel D, Wolf H, Lechncr F, Blumel G: Prophylaxis of deep-vein thrombosis in high risk patients undergoing total hip replacement with low molecular weight heparin plus dihydroergotamine. Arzneimittelforschung 1987;37:839-843.
27. Hess P. Oertli D, Durig M, Laffer U, Fridrich R, Jager K, Harder F: Thromboembolieprophylaxe in der Hüfttraumatologie: niedermolekulares Heparin vs, Dextran. Helv Chir Acta 1992;58:931-935
28. Lassen MR, Borris LC, Christiansen HM, Moller-Larsen F, Knudsen VE, Boris P, Nehen AM, Jurik AG, de Carvalho A, Nielsen BW, Lucht U: Prevention of thromboembolism in hip-fracture patients. Comparison of low-dose heparin and low-molecular-weight heparin combined with dihydroergotamine. Arch Orthop Trauma Surg 1989;108:10-13.
29. Binsack T, Zöllner M, Schimmig I, Wirth C, Moser E, Riess H, Hiller E: Thrombosis prophylaxis with LMW heparin and sodium heparin in patients with total hip replacement. Thromb Res 1986;suppl VI:83.
30. Leclerc J, Geerts W, Desjardins L, Jobin F, Delorme F, Bourgouin J: A randomized trial of Enoxaparin for the prevention of deep-vein thrombosis after major knee surgery. Thromb Haemost 1991:65(suppl): 753.
31. Mätzsch T, Bergqvist D, Fredin H, Hedner U: Safety and efficacy of a low molecular weight heparin (Logi-parin) vs, dextran as prophylaxis against thrombosis after total hip replacement. Acta Chir Scand 1988; 543(suppl):80-84.
32. Gerhart TN, Yett HS, Robertson LK, Lee MA. Smith M, Salzman EW: Low-molecular-weight hepa-rinoid compared with warfarin for prophylaxis of deep-vein thrombosis in patients who are operated on for fracture of the hip. J Bone and Joint Surg 1991;73:494-502.
33. Bergqvist D: Orgaran in hip fracture surgery. Haemostasis 1992,22:104-108.
34. Heit C, Kessler C, Mammen E, Kwaan H, Neemah J, Cabanas V, Trowbridge A, Holloway S, Davidson B: Efficacy and safety of RD heparin (a LMWH) vs, warfarin for prevention of deep-vein thrombosis after hip or knee replacement. Blood 1991;78(suppl): 187a.
35. Haas S, Fritsche H, Ritter H, Stemberger A, Wendt P, Zeisel HJ, Lech-ner F, Blumel G: Thrombosis prophylaxis with low-molecular weight heparin in total hip replacement. Thromb Haemost 1985;54:319.
36. Thompson SG. Pocock SJ: Can metaanalyses be trusted? (see comments). Lancet 1991;338:1127-1130.
37. Imperiale TF, Speroflf T: A metaanalysis of methods to prevent venous thromboembolism following total hip replacement. JAMA 1994; 271:1780-1785.